Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis
The examined results provide crucial recommendations for optimizing the administration of Abraxane, enhancing its effectiveness, and mitigating potential adverse effects. This knowledge will substantially facilitate the implementation of the substance in clinical settings.
Authors
- Mei Zeng
- Qian Dai (ORCID: https://orcid.org/0000-0002-9887-0156)
- Dachuan Liu (ORCID: https://orcid.org/0000-0003-3232-4707)
- Rutie Yin (ORCID: https://orcid.org/0000-0002-9221-6727)
- Yuanqiong Duan (ORCID: https://orcid.org/0000-0002-5455-1444)
- Ying Wang (ORCID: https://orcid.org/0000-0003-4524-1812)
- S.P. Lu
Institutions
- North Sichuan Medical University (CN)
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3389/fphar.2024.1448144
- Citations
- 12
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- National Natural Science Foundation of China
- Department of Science and Technology of Sichuan Province
- Centre Scientifique et Technique du Bâtiment